Laura G. Hansen
Investor Relations Contact at DENALI THERAPEUTICS INC.
Profile
Laura G.
Hansen is currently the Vice President-Investor Relations at Denali Therapeutics, Inc. She previously worked as the Director-Corporate Communications at Corvas International, Inc. from 2001 to 2002, Director-Corporate Communications at FibroGen, Inc. from 2002 to 2012, Senior Director-Corporate Communications at Threshold Pharmaceuticals, Inc. from 2012 to 2016, and Vice President-Investor Relations at Aimmune Therapeutics, Inc. from 2016 to 2019.
She also worked as the Vice President-Corporate Affairs at BlackThorn Therapeutics, Inc. from 2019 to 2020.
Dr. Hansen received her undergraduate and doctorate degrees from The University of Texas at Austin.
Laura G. Hansen active positions
| Companies | Position | Start |
|---|---|---|
| DENALI THERAPEUTICS INC. | Investor Relations Contact | - |
Former positions of Laura G. Hansen
| Companies | Position | End |
|---|---|---|
BlackThorn Therapeutics, Inc.
 BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA. | Corporate Officer/Principal | 2020-08-31 |
| AIMMUNE THERAPEUTICS, INC. | Investor Relations Contact | 2019-02-28 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Investor Relations Contact | 2016-01-31 |
| FIBROGEN, INC. | Public Communications Contact | 2012-06-30 |
| Corvas International, Inc. | Public Communications Contact | 2002-06-30 |
Training of Laura G. Hansen
| The University of Texas at Austin | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| DENALI THERAPEUTICS INC. | Health Technology |
| Private companies | 4 |
|---|---|
| Corvas International, Inc. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
BlackThorn Therapeutics, Inc.
BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Laura G. Hansen
